eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2023
vol. 9
 
Share:
Send email
Share:
abstract:
Original paper

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease

Toru Ishikawa
1
,
Nanako Terai
2
,
Takanori Igarashi
1
,
Shun Yamazaki
1
,
Takamasa Kobayashi
1
,
Toshifumi Sato
1
,
Akito Iwanaga
1
,
Tomoe Sano
1
,
Junji Yokoyama
1
,
Terasu Honma
1

  1. Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan
  2. Department of Radiography, Saiseikai Niigata Hospital, Niigata, Japan
Clin Exp HEPATOL 2023; 9, 2: 172-178
DOI: https://doi.org/10.5114/ceh.2023.127813
Online publish date: 2023/06/23
View full text Get citation
 
PlumX metrics:
Aim of the study:
Owing to the association between non-alcoholic fatty liver disease (NAFLD) and dyslipidemia, there is a need for new treatment strategies to manage both conditions concomitantly. Our aim in this study was to evaluate the effectiveness of pemafibrate in alleviating dyslipidemia-associated NAFLD, including the evaluation of its effects on liver function and body composition.

Material and methods:
The study sample included 67 patients with dyslipidemia-associated NAFLD (29 males, mean age 65.7 years [range, 58.4-73.7]) who were administered pemafibrate continuously for a period of at least 12 months, between June 2019 and January 2022. Outcomes were the change in body composition indices (visceral adipose tissue index – VATI, subcutaneous adipose tissue index – SATI, and skeletal muscle index – SMI), lipid biochemistry, and liver function, reserve, and fibrosis score, from baseline to the 12-month time point of pemafibrate treatment.

Results:
Pemafibrate treatment improved liver function (alanine aminotransferase, aspartate aminotransferase, g-glutamyl transpeptidase, and alkaline phosphatase), and lipid biochemistry (triglycerides and total cholesterol). Improvements in ferritin and hepatic reserve (Mac-2 binding protein, albumin-to-bilirubin score, and NAFLD fibrosis score) were also observed, as well as a decrease in SATI.

Conclusions:
Pemafibrate improved dyslipidemia, liver function, and hepatic reserve. The positive effects of pemafibrate on body composition likely contributed to the improvements in liver function. Longer-term treatment may be necessary to influence VATI and thus to further evaluate the relationship between improved body composition and NAFLD with pemafibrate treatment.

keywords:

non-alcoholic fatty liver disease, pemafibrate, liver function, liver fibrosis, body composition
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.